

---

# Contents

<b>1 Complexity of Biologic CMC Regulation .....</b>	<b>1</b>
1.1 What's in a Name.....	1
1.1.1 Terms: "Biologic" and "Biological" .....	2
1.1.2 Terms: "Biotechnology-Derived" and "Biopharmaceutical" .....	2
1.1.3 Landscape of Pharmaceutical Terminology .....	3
1.2 Navigating United States Biologic Regulation .....	3
1.2.1 Food, Drug, and Cosmetic (FD&C) Act .....	4
1.2.2 Public Health Service (PHS) Act .....	4
1.2.3 "Specified Biologics" Under the PHS Act .....	6
1.2.4 Confusion About Which Law Applies .....	6
1.2.5 Significant CMC Regulatory Differences Between the Two Laws .....	8
1.2.6 Two FDA Centers to Execute Two Pharmaceutical Laws.....	15
1.3 Navigating the European Union Biologic Regulation .....	15
1.3.1 Legal Definition of "Biological" in the EU .....	15
1.3.2 Biologic Regulation During Clinical Development.....	16
1.3.3 Biologic Regulation at Market Approval .....	16
1.4 Embrace the Complexity.....	17
References.....	18
<b>2 Biologics Are Not Chemical Drugs .....</b>	<b>21</b>
2.1 Regulatory Authorities Agree .....	22
2.1.1 FDA's Viewpoint on Differences.....	22
2.1.2 EMA's Viewpoint on Differences.....	22
2.1.3 ICH's Position on Differences.....	23
2.2 Three Major Differences of Biologics .....	24
2.2.1 Use of Living Production Systems .....	24
2.2.2 Impact of Manufacturing Process on the Product.....	25
2.2.3 Complexity of the Produced Biologic .....	26
2.3 Biosimilar, Not "Biogeneric" .....	27
2.3.1 EMA: Biosimilar Medicines .....	27
2.3.2 Health Canada: Subsequent Entry Biologics.....	28
2.3.3 WHO: Similar Biotherapeutic Products .....	29

2.3.4	FDA: Follow-On Protein Products .....	29
2.3.5	FDA: Biosimilar Biological Products .....	30
2.4	Never Say Never .....	31
	References.....	32
<b>3</b>	<b>An Effective CMC Strategy is Possible .....</b>	<b>35</b>
3.1	Forces That Shape.....	36
3.1.1	Risk Tolerance.....	36
3.1.2	Resource Allocation .....	37
3.1.3	Never Enough.....	38
3.2	Five Core Strategic Elements.....	39
3.2.1	Embrace All CMC Regulatory Compliance Activities .....	39
3.2.2	Address CMC for Specific Biologic Manufacturing Processes.....	40
3.2.3	Address CMC for Specific Biologic Products.....	40
3.2.4	Align to Strategic ICH Guidances (Q8/Q9/Q10/Q11) .....	42
3.2.5	Meet Minimum CGMP Requirements .....	47
3.3	Central Role of Clinical Phase-Appropriate .....	52
3.3.1	Strategy Embraced by FDA.....	53
3.3.2	Strategy Encouraged by EMA.....	54
3.3.3	Strategy Consistent with ICH.....	55
3.3.4	Strategy Endorsed by Industry .....	55
3.4	One Size Does Not Fit All .....	55
	References.....	56
<b>4</b>	<b>Challenge of Adventitious Agent Control .....</b>	<b>59</b>
4.1	Prions .....	60
4.1.1	Prion Risk from Biologics.....	61
4.1.2	Testing for Presence of Prions.....	61
4.1.3	Prion Risk Minimization Strategies .....	61
4.1.4	CMC Strategy Tip: Necessity of Risk Review .....	68
4.2	Viruses.....	68
4.2.1	Virus Risk from Biologics.....	69
4.2.2	Testing for Presence of Viruses .....	70
4.2.3	Virus Risk Control Strategies .....	71
4.2.4	CMC Strategy Tip: Stay Alert for Warning Signs .....	84
4.3	Mycoplasmas .....	86
4.3.1	Mycoplasma Risk from Biologics.....	86
4.3.2	Testing for Presence of Mycoplasmas.....	86
4.3.3	Mycoplasma Risk Control Strategies .....	87
4.3.4	CMC Strategy Tip: Never Let Your Guard Down .....	90
4.4	Bacteria/Fungi.....	91
4.4.1	Bacteria/Fungi Risk from Biologics.....	91
4.4.2	Testing for Presence of Bacteria/Fungi .....	93

---

4.4.3	Bacteria/Fungi Risk Controls Strategies .....	94
4.4.4	CMC Strategy Tip: Not All Discoveries Have Been Made Yet .....	96
4.5	“Not Detected” Is Not Confirmation of Absence .....	97
	References.....	98
<b>5</b>	<b>Source Materials for Biologics .....</b>	<b>105</b>
5.1	Source Material Differences .....	105
5.1.1	Chemical Drug Source .....	105
5.1.2	Biologic Source .....	106
5.2	Cell Banks for Protein Manufacture .....	107
5.2.1	Developmental Genetics.....	107
5.2.2	Criticality of Proper Cloning.....	109
5.2.3	Importance of Adequate Documentation .....	113
5.2.4	Cell Banking.....	116
5.3	Virus Seed Banks .....	124
5.3.1	Viral Vaccine Production.....	124
5.3.2	Gene Therapy Vector Production .....	125
5.4	Transgenic Banks for Biopharmaceutical Production .....	127
5.4.1	Transgenic Animal Banks .....	127
5.4.2	Transgenic Plant Banks .....	128
5.5	Allogeneic Cell-Based Medicine Cell Banks .....	130
5.6	Myth Busting .....	130
5.6.1	Myth #1: Both Master and Working Cell Banks Are Necessary.....	130
5.6.2	Myth #2: Acceptability of Master Cell Bank for Commercialization .....	131
5.6.3	Myth #3: Multiple Master Cell Banks.....	131
5.6.4	Myth #4: Don’t Be Too Concerned About the Working Cell Bank .....	132
	References.....	133
<b>6</b>	<b>Manufacture of the Biologic API.....</b>	<b>139</b>
6.1	Numerous Genetic Expression Systems for Biologics.....	140
6.2	Bioreactor Cell Culture Production .....	142
6.2.1	Choice of Bioreactor Design/Operational Mode.....	143
6.2.2	Criticality of Genetic Stability of the Production Cultures.....	145
6.2.3	Clinical Phase-Appropriate Cell Culture Control.....	150
6.3	Other Production Systems.....	154
6.3.1	Production by Transgenic Animals .....	155
6.3.2	Production by Transgenic Plants .....	156
6.3.3	Production of Live Viruses .....	157
6.3.4	Production of Cell-Based Medicines.....	159

6.4	Purification of Proteins .....	160
6.4.1	Design of the Purification Process.....	160
6.4.2	Clinical Phase-Appropriate Purification Process Control .....	163
6.5	Purification of Viruses.....	168
6.6	Process Validation for the Twenty-First Century .....	169
6.6.1	Process Validation Must Be Complete for Biologics .....	169
6.6.2	No Magic “3 Run” Formula .....	172
6.7	Don’t Forget the Bio-facility Description .....	173
6.8	Anything That Can Go Wrong, Will.....	174
	References.....	175
<b>7</b>	<b>The Biologic Final Product Process.....</b>	<b>179</b>
7.1	Chemical Modifications of Protein API.....	180
7.1.1	Pegylation.....	180
7.1.2	Conjugation with a Chemical Linker .....	181
7.1.3	Conjugate Vaccines .....	182
7.2	Formulation: Not for the Fainthearted .....	183
7.2.1	Abundance of Excipients Available .....	183
7.2.2	Not All Excipients Carry the Same Regulatory Risk.....	186
7.2.3	Formulation Development: A Wise Investment Choice .....	187
7.2.4	Formulation Surprises with Biologics.....	188
7.3	Container Closure Materials Are Not Inert.....	189
7.3.1	Abundance of Container Closure Systems Available .....	189
7.3.2	Two-Way Interactions.....	189
7.3.3	Container Closure Surprises with Biologics .....	191
7.4	Assembly of the Final Product.....	192
7.4.1	Stringent Aseptic Processing.....	192
7.4.2	Establishing Control of the Final Product Manufacture .....	193
	References.....	196
<b>8</b>	<b>Complex Process-Related Impurities .....</b>	<b>199</b>
8.1	Road Map for Process-Related Impurities .....	200
8.1.1	Process-Related Impurities Defined .....	200
8.1.2	Road Map for Chemical Drugs .....	200
8.1.3	Road Map for Biologics .....	201
8.1.4	Clinical Phase-Appropriate Approach.....	201
8.2	Living System-Related Impurities .....	203
8.2.1	Impurities from Cell Culture Processes.....	203
8.2.2	Impurities from Transgenic Animal Processes .....	209
8.2.3	Impurities from Transgenic Plant Processes .....	210

8.2.4	Impurities from Virus Processes for Vaccines .....	210
8.2.5	Impurities from Virus Processes for Gene Therapy .....	211
8.2.6	Impurities from Cell-Based Medicine Processes .....	213
8.3	Purification-Related Impurities .....	213
8.4	Extractables and Leachables .....	214
8.5	Biosimilar Impact .....	216
8.6	Unknown Unknowns .....	216
	References .....	217
<b>9</b>	<b>Molecular Structural Analysis</b> .....	<b>221</b>
9.1	Protein Characterization Methods .....	222
9.1.1	Plethora of Analytical Methods .....	222
9.1.2	Qualified, Not Validated .....	223
9.2	No Lack of Protein Structural Variants .....	223
9.2.1	Primary Amino Acid Sequence Variants .....	223
9.2.2	Posttranslational Modification Variants .....	226
9.2.3	Higher-Order Structure Variants .....	227
9.2.4	Consequences of So Many Variants .....	229
9.3	Clinical Phase-Appropriate Characterization .....	229
9.3.1	Early Clinical Stage: Adequate but Limited .....	229
9.3.2	Later Clinical Stage: Knowledge Development ....	229
9.3.3	Market Approval Stage: Thorough and Complete .....	230
9.4	Case Examples: Proteins .....	233
9.5	Structural Analysis: Gene Therapy Vectors .....	234
9.6	Structural Analysis: Whole Cells .....	235
9.7	Prognosticating .....	235
	References .....	236
<b>10</b>	<b>Functional Activity (Potency)</b> .....	<b>239</b>
10.1	Pharmaceutical Strength .....	239
10.1.1	Content Equals Strength: Chemical Drug .....	240
10.1.2	Biological Activity, Not Content: Biologic .....	240
10.2	Priceless Potency .....	240
10.3	Functional Activity Assays for Potency .....	242
10.3.1	Bioassays .....	242
10.3.2	Surrogate (Analytical) Assays .....	246
10.3.3	Assay Matrix .....	248
10.4	Progressive Potency Assay Implementation .....	250
10.4.1	Potency for Early-Stage Clinical Development .....	251
10.4.2	Potency for Late-Stage Clinical Development .....	251
10.4.3	Potency for Market Approval .....	252
10.5	Are We There Yet? .....	252
	References .....	254

<b>11</b>	<b>Setting Specifications and Expiry Dates .....</b>	<b>257</b>
11.1	QC Testing: General Principles .....	257
11.1.1	A Component of the Overall Control Strategy.....	257
11.1.2	CQAs Require Testing.....	258
11.1.3	Testing Interrelationship: Characterization, Release, Stability .....	258
11.2	Categories of QC Testing .....	259
11.2.1	Appearance/Description .....	259
11.2.2	Identity .....	260
11.2.3	Purity/Impurities.....	261
11.2.4	Potency .....	262
11.2.5	Quantity .....	263
11.2.6	General Quality Attributes .....	263
11.2.7	Recommended Testing Programs.....	263
11.3	Strategy for Setting Release Specifications.....	263
11.3.1	Clinical Phase-Appropriate Approach.....	264
11.3.2	Justifying Four Types of Specifications for Market Approval.....	265
11.3.3	Post-Market Approval Specification Adjustment .....	271
11.3.4	Specification Case Examples: Successes and Problems .....	272
11.3.5	Specification Setting for Biosimilars.....	275
11.4	Strategy for Expiry Dating .....	275
11.4.1	Biologic Stability Program: Four Similarities to Chemical Drugs.....	275
11.4.2	Biologic Stability Program: Four Differences to Chemical Drugs.....	277
11.4.3	Clinical Phase-Appropriate Approach.....	279
11.4.4	In-Use Period Assignment for Market Approval .....	282
11.4.5	Transportation Qualification Studies for Market Approval.....	283
11.4.6	Expiry Dating Case Examples: Successes and Problems .....	284
	References .....	286
<b>12</b>	<b>Demonstrating Product Comparability .....</b>	<b>291</b>
12.1	Process Change Is Inevitable.....	292
12.1.1	Process Change: “Value Added” .....	292
12.1.2	Process Change: “Anytime, Anywhere” .....	292
12.2	Goal of the Comparability Study.....	293
12.2.1	Biologic: “Highly Similar”.....	294
12.2.2	Chemical Drug: “Equivalent”.....	294
12.3	Comparability Study Design .....	295
12.3.1	Risk-Based .....	295
12.3.2	Sequential .....	297

---

12.3.3	Clinical Phase-Appropriate .....	303
12.3.4	For Nonprotein Biologics Also .....	307
12.4	Comparability Protocol .....	308
12.4.1	Four Elements of the Protocol.....	308
12.4.2	Value Added .....	308
12.4.3	Reaching Agreement with the FDA .....	309
12.4.4	EMA Approach .....	310
12.5	Extreme Comparability: Biosimilars.....	310
12.5.1	Demonstrating Analytical Biosimilarity .....	311
12.5.2	Limitations of Manufacturing Knowledge .....	311
12.5.3	Warning About Changing the Expression System .....	312
12.5.4	Analytical Biosimilarity: Successes and Failures .....	313
12.6	Surprises Happen.....	315
	References .....	316
<b>13</b>	<b>CMC-Focused Regulatory Meetings .....</b>	<b>321</b>
13.1	Critical Need to Talk.....	321
13.2	Meetings with FDA .....	323
13.2.1	PDUFA Meetings .....	323
13.2.2	BsUFA Meetings .....	326
13.3	Meetings with EMA .....	327
13.4	Critical Need to Listen.....	327
	References .....	329
	<b>Index.....</b>	<b>331</b>

The Challenge of CMC Regulatory Compliance for  
Biopharmaceuticals

Geigert, J.

2013, XXIX, 338 p. 24 illus., 17 illus. in color., Hardcover

ISBN: 978-1-4614-6915-5